Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 7Active not recruiting 4Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Rhabdomyosarcoma 2Gestational Trophoblastic Disease 2Stage I Mixed Cell Type Kidney Wilms Tumor 1Sarcoma, Ewing 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Rhabdomyosarcoma, Embryonal 1Pleuropulmonary blastoma 1Histiocytoma, Malignant Fibrous 1Dermatofibrosarcoma 1

Interventions

Temozolomide 7Vincristine 6Cyclophosphamide 5fludarabine 3Irinotecan 3pegfilgrastim 2irinotecan sucrosofate 2Zoledronic Acid 2Vinorelbine 2Filgrastim 2Dactinomycin 2talazoparib 1silmitasertib 1regorafenib 1pegylated granulocyte colony-stimulating factor 1pazopanib 1liposomal doxorubicin 1fludarabine phosphate 1cabozantinib 1atezolizumab 1amino-acid, glucose, and electrolyte solution 1Whole-Body Irradiation 1Vorinostat 1Tacrolimus 1Radiotherapy 1Mesna 1Melphalan 1Influenza Vaccines 1Indocyanine Green 1Immunotherapy, Adoptive 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Rhabdomyosarcoma × Dactinomycin × Clear all
NCT06023641 2025-08-19

Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

St. Jude Children's Research Hospital

Phase 2 Recruiting
135 enrolled
Sarcoma

Rhabdomyosarcoma

NCT04625907 2024-05-23

FaR-RMS

University of Birmingham

Phase 1/2 Recruiting
1,672 enrolled
Sarcoma

Rhabdomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡